Lindsay Ryland, PhD, MBA

Lindsay Ryland, PhD, MBA
Director, Business Development
Mid-Atlantic South Region


Lindsay Ryland, Ph.D., MBA comes to Champions Oncology with previous business development and project management experience from SAI MedPartners where she served as clinical project lead for major pharmaceutical companies including AbbVie, Amgen, Actelion, Janssen, Bristol Myers Squibb, Baxter, Cell Therapeutics, Jazz Pharmaceuticals, Pharmacyclics, etc.  She has extensive expertise in oncology research, as well as monitoring the competitive oncology landscape for both solid and non-solid tumors.  Dr. Ryland’s project experience spans several oncology indications including melanoma, NSCLC, prostate cancer, ovarian cancer, metastatic colorectal cancer and hematological malignancies (e.g., CLL, iNHL, AML, ALL, etc.). While at SAI, Lindsay was tasked with managing multiple consultants and analysts in developing comprehensive business intelligence research and strategic analysis to support client needs. She routinely targeted scientific conferences (e.g. ASCO, ESMO, AACR, ASH, EHA, etc) to gain clinical insights from KOLs in the field.  Dr. Ryland also promoted business development efforts by generating proposals and delivering presentations that were driven by active primary and secondary research that resulted in achievement of projects valued over $2,000,000.

Dr. Ryland has multiple peer-reviewed publications in a variety of high-impact journals and also has presented her clinical research at several international conferences.  Lindsay received a Ph.D. in Pharmacology from Pennsylvania State College of Medicine where her thesis research was focused on nanoliposomal drug delivery systems to treat CLL and other hematological malignancies.  In addition, Dr. Ryland earned an M.B.A. from Pennsylvania State University and a B.S. in Pharmaceutical Product Development from West Chester University of Pennsylvania, graduating Summa Cum Laude.

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology